Markets
markets

Goldman hikes year-end gold price forecast to $5,400 per ounce as private investors and central banks compete for the shiny stuff

Goldman Sachs has raised its December 2026 gold price forecast to $5,400 per ounce, up from the previous $4,900 target, citing strong demand from private sector investors using gold as a hedge against global policy risks, according to a note released late Tuesday.

The revised price target reflects a 17% increase from Januarys month-to-date average price, with continued central bank buying as the biggest driver of the forecast (accounting for 14 percentage points of the expected appreciation), while ETF inflows add another 3 pp — supported by an assumed Fed rate cut this year.

Central banks have been on a gold-buying spree since 2022, after the freezing of Russias foreign reserves, helping push prices up 15% in 2023 and 26% in 2024. But Goldman analysts noted that the rally accelerated in 2025 as competition between central banks and private investors for the limited bullion intensified — driving prices up another 67% last year, with recent tensions over Greenland only adding to the momentum.

That private sector demand now extends well beyond ETF inflows. Goldman said buying is increasingly coming from a new class of investors seeking protection against macro policy risk and currency debasement, including purchases from high-net-worth families and call option buying — flows that are hard to track but have become a significant incremental source of demand.

Goldman assumed these macro-related sticky hedges will persist through 2026 — unlike those tied to the 2024 US election, which unwound quickly once the outcome was clear.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.